BUZZ-Legend Biotech gains as key shareholder to deconsolidate co

Reuters10-22

** Shares of cancer therapy maker Legend Biotech up about 8% at $46.80 before the bell

** Board of Genscript , a key shareholder of LEGN, has "resolved to deconsolidate the Legend Group", the life sciences firm said on Tuesday

** Genscript said that after the deconsolidation, it will account for its investment in LEGN using equity method

** Genscript expects to recognize a one-time gain related to the deconsolidation

** As of Dec. 31, 2023, Genscript owned about 174.5 million shares of LEGN

** As of last close, LEGN down about 28% YTD

(Reporting by Bhanvi Satija in Bengaluru)

((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2477389330?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-22 18:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477389330","market":"us","top_or_hot":-1,"title":"BUZZ-Legend Biotech gains as key shareholder to deconsolidate co","media":"Reuters","content":"<html><body><p>** Shares of cancer therapy maker Legend Biotech    up about 8% at $46.80 before the bell </p><p>   ** Board of Genscript   , a key shareholder of LEGN, has \"resolved to deconsolidate the Legend Group\", the life sciences firm said on Tuesday </p><p>   ** Genscript said that after the deconsolidation, it will account for its investment in LEGN using equity method </p><p>   ** Genscript expects to recognize a one-time gain related to the deconsolidation </p><p>   ** As of Dec. 31, 2023, Genscript owned about 174.5 million shares of LEGN </p><p> ** As of last close, LEGN down about 28% YTD</p><p> (Reporting by Bhanvi Satija in Bengaluru)</p><p>((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Legend Biotech gains as key shareholder to deconsolidate co</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Legend Biotech gains as key shareholder to deconsolidate co\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-22 18:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>** Shares of cancer therapy maker Legend Biotech    up about 8% at $46.80 before the bell    ** Board of Genscript   , a key shareholder of LEGN, has \"resolved to deconsolidate the Legend Group\", the ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LEGN","symbol_name":"传奇生物","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2477389330","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477389330","pubTimestamp":1729592824,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"** Shares of cancer therapy maker Legend Biotech    up about 8% at $46.80 before the bell    ** Board of Genscript   , a key shareholder of LEGN, has \"resolved to deconsolidate the Legend Group\", the life sciences firm said on Tuesday    ** Genscript said that after the deconsolidation, it will account for its investment in LEGN using equity method    ** Genscript expects to recognize a one-time gain related to the deconsolidation    ** As of Dec. 31, 2023, Genscript owned about 174.5 million shares of LEGN  ** As of last close, LEGN down about 28% YTD ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LEGN":"传奇生物","BK1583":"高瓴概念","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","BK4505":"高瓴资本持仓","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK1141":"生命科学工具和服务","BK4585":"ETF&股票定投概念","BK4139":"生物科技","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","BK1576":"医药外包概念","BK4588":"碎股","01548":"金斯瑞生物科技"},"translate_title":"BUZZ-Legend Biotech成为主要股东，分拆公司","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LEGN":1,"01548":0.9},"content_text":"** Shares of cancer therapy maker Legend Biotech    up about 8% at $46.80 before the bell    ** Board of Genscript   , a key shareholder of LEGN, has \"resolved to deconsolidate the Legend Group\", the life sciences firm said on Tuesday    ** Genscript said that after the deconsolidation, it will account for its investment in LEGN using equity method    ** Genscript expects to recognize a one-time gain related to the deconsolidation    ** As of Dec. 31, 2023, Genscript owned about 174.5 million shares of LEGN  ** As of last close, LEGN down about 28% YTD (Reporting by Bhanvi Satija in Bengaluru)((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2477389330"}